Future-Proofing: Inclusive and Protective Patient Strategies
29 Aug 2024
25m
BioSpace · Business
BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Episodes
A Tough Ending, New Beginnings and China-U.S. Biopharma Relations
28 Aug 2024
15m
New IRA Drug Prices, Lots of Layoffs, Moderna’s Vaccine Opportunity
21 Aug 2024
16m
Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations
15 Aug 2024
23m
Lykos Rejection, Pfizer’s RSV Win, Lilly Vs. Novo and More
14 Aug 2024
21m
Pharma Campaign Contributions, Vaccine Hiccups and Lykos’ Moment of Truth
07 Aug 2024
18m
The Political Shape of the Future Clinical Trial Space
01 Aug 2024
22m
2 Earnings Bonanza, M&A Accelerates and Alzheimer’s Data
31 Jul 2024
18m
Layoffs Persist, GLP-1s Launch for Weight Loss in China
24 Jul 2024
15m
Who Is Driving The Bus - Drug Developers & Healthcare Providers or AI?
18 Jul 2024
19m
Pfizer’s Oral GLP-1 Push, Lilly Vs. Novo and PBMs Under Pressure
17 Jul 2024
13m
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists
10 Jul 2024
18m
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
03 Jul 2024
15m
DE&I: Understanding That We Don’t Understand at Molecular Level
02 Jul 2024
23m
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights
26 Jun 2024
12m
BioSpace at #DIA2024: Workforce Trends, Trial Design, Peter Marks & Recap
20 Jun 2024
9m
Challenging Research Models to Improve Health Equity
20 Jun 2024
23m
BIOSECURE’s Surprise Absence, the $100+ Billion Future Weight-Loss Market, DIA and More
19 Jun 2024
14m
BioSpace at #DIA2024: Convergence and Collaboration
17 Jun 2024
5m
Donanemab’s Promise, BIO Wrap and Mass Layoffs
12 Jun 2024
16m
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.